BNT162 Vaccine

Displaying 1 - 4 of 4CSV
Klein, N. P., Demarco, M., Fleming-Dutra, K. E., Stockwell, M. S., Kharbanda, A. B., Gaglani, M., Rao, S., Lewis, N., Irving, S. A., Hartmann, E., Natarajan, K., Dalton, A. F., Zerbo, O., DeSilva, M. B., Konatham, D., Stenehjem, E., Rowley, E. A. K., Ong, T. C., Grannis, S. J., … Link-Gelles, R. (2023). Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics, 151(5). https://doi.org/10.1542/peds.2022-060894
Publication Date
Liu, C., Lee, J., Ta, C., Soroush, A., Rogers, J. R., Kim, J. H., Natarajan, K., Zucker, J., Perl, Y., & Weng, C. (2022). Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis. JMIR Public Health and Surveillance, 8(5), e35311. https://doi.org/10.2196/35311
Publication Date
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D. G., Karim, F., Bernstein, M., Lustig, G., Archary, D., Smith, M., Ganga, Y., Jule, Z., Reedoy, K., Hwa, S.-H., … Sigal, A. (2021). Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 602(7898), 654–656. https://doi.org/10.1038/s41586-021-04387-1
Publication Date
Cele, S., Karim, F., Lustig, G., San, J. E., Hermanus, T., Tegally, H., Snyman, J., Moyo-Gwete, T., Wilkinson, E., Bernstein, M., Khan, K., Hwa, S.-H., Tilles, S. W., Singh, L., Giandhari, J., Mthabela, N., Mazibuko, M., Ganga, Y., Gosnell, B. I., … Sigal, A. (2022). SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host & Microbe, 30(2), 154-162.e5. https://doi.org/10.1016/j.chom.2022.01.005
Publication Date